Stealth BioTherapeutics (NASDAQ:MITO) Earns Buy Rating from HC Wainwright

Stealth BioTherapeutics (NASDAQ:MITO)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a note issued to investors on Friday, reports. They presently have a $30.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 156.41% from the company’s previous close.

Separately, Zacks Investment Research cut HEXO from a “hold” rating to a “sell” rating in a report on Wednesday, May 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $24.83.

Shares of NASDAQ:MITO opened at $11.70 on Friday. The company has a fifty day moving average of $12.49. Stealth BioTherapeutics has a 52-week low of $11.11 and a 52-week high of $20.99.

Stealth BioTherapeutics (NASDAQ:MITO) last issued its earnings results on Wednesday, May 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.14. As a group, equities research analysts anticipate that Stealth BioTherapeutics will post -0.18 earnings per share for the current year.

An institutional investor recently bought a new position in Stealth BioTherapeutics stock. Dean Capital Investments Management LLC purchased a new stake in Stealth BioTherapeutics Corp (NASDAQ:MITO) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 50,420 shares of the company’s stock, valued at approximately $646,000. Dean Capital Investments Management LLC owned about 0.18% of Stealth BioTherapeutics as of its most recent SEC filing. 1.09% of the stock is currently owned by institutional investors.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Featured Article: What is the Current Ratio?

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with's FREE daily email newsletter.